| |
Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) or AL-335 and ODV in the Treatment of Chronic Hepatitis C Infection - new phase 2 study
|
| |
| |
https://clinicaltrials.gov/ct2/show/NCT02765490?term=NCT02765490&rank=1
The purpose of this study is to evaluate the efficacy (proportion of subjects with SVR12), safety and tolerability of an 8- and 6-week treatment regimen of AL-335, odalasvir (ODV) and simeprevir (SMV) and a treatment regimen of AL-335 and ODV in chronic HCV genotype 1-6 infected subjects with and without cirrhosis.
A Phase 2b, Multicenter, Randomized, Open-label Study to Investigate the Efficacy, Safety and Pharmacokinetics of Different Treatment Regimens of AL-335, Odalasvir, and Simeprevir in Treatment-naive and Treatment-experienced Subjects With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, 5, and 6 Infection, With and Without Cirrhosis
This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified May 2016 by Janssen Research & Development, LLC
|
|
| |
| |
|
|
|
